ctrl K

Price Alert

Inhibikase Therapeutics I... (IKT)

NASDAQ: IKT · Real-Time Price · USD

1.71

0.01 (0.59%)

At close: Aug 20, 2025, 9:46 AM

Inhibikase Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	56.49M	9.17M	7.19M	40.75M
Short-Term Investments	41.05M	4.09M	15.86M	n/a
Long-Term Investments	n/a	n/a	-15.85M	n/a
Other Long-Term Assets	47.1K	n/a	15.85M	n/a
Receivables	n/a	n/a	39.88K	110.14K
Inventory	n/a	n/a	1.12M	107K
Other Current Assets	826.47K	739.18K	163.45K	1.5M
Total Current Assets	98.45M	14.21M	24.37M	42.47M
Property-Plant & Equipment	101.44K	295.6K	565.17K	n/a
Goodwill & Intangibles	n/a	n/a	n/a	n/a
Total Long-Term Assets	148.54K	295.6K	565.17K	n/a
Total Assets	98.6M	14.51M	24.94M	42.47M
Account Payables	943.02K	646.77K	1.15M	1.09M
Deferred Revenue	n/a	n/a	n/a	n/a
Short-Term Debt	110.52K	381.78K	145.84K	248.91K
Other Current Liabilities	-110.52K	635.45K	1.79M	n/a
Total Current Liabilities	3.73M	3.44M	3.7M	4.05M
Long-Term Debt	n/a	n/a	n/a	n/a
Other Long-Term Liabilities	n/a	n/a	n/a	n/a
Total Long-Term Liabilities	n/a	90.12K	205.45K	2.72M
Total Liabilities	3.73M	3.53M	3.9M	4.05M
Total Debt	110.52K	622K	351.29K	248.91K
Common Stock	69.36K	6.19K	25.23K	25.16K
Retained Earnings	-94.42M	-66.9M	-47.87M	-29.82M
Comprehensive Income	-37.25K	877.00	104.72K	-0.00
Shareholders Equity	94.87M	10.98M	21.04M	38.42M
Total Investments	41.05M	4.09M	15.86K	n/a